Journal Mobile Options
Table of Contents
Vol. 42, No. 6, 2009
Issue release date: October 2009
Psychopathology 2009;42:375–379
(DOI:10.1159/000236909)

Negative Performance Beliefs and Negative Symptoms in Individuals at Ultra-High Risk of Psychosis: A Preliminary Study

Perivoliotis D. · Morrison A.P. · Grant P.M. · French P. · Beck A.T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Negative beliefs regarding task performance have been shown to correlate with negative symptom severity in patients with chronic schizophrenia. We conducted a pilot study to determine whether the association also exists in individuals at ultra-high risk of psychosis. Sampling and Methods: The sample consisted of 38 individuals at ultra-high risk of psychosis and 51 controls. All participants completed the Abbreviated Dysfunctional Attitudes Scale; the ultra-high-risk participants were assessed with the Positive and Negative Syndrome Scale. Results: High-risk participants endorsed negative performance beliefs to a greater extent than controls and these beliefs were associated with greater negative symptom severity, independent of depression and positive symptoms. Conclusions: The findings are consistent with previous results in chronic patients, and suggest that negative performance beliefs may be a promising psychological factor worthy of further attention in individuals at high risk of psychosis. Longitudinal research with more comprehensive assessment is needed to elucidate the potential role of negative performance beliefs in this population.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bromet EJ, Naz B, Fochtmann LJ, Carlson GA, Tanenberg-Karant M: Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia. Schizophr Bull 2005;31:639–649.
  2. Erhart SM, Marder SR, Carpenter WT: Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 2006;32:234–237.
  3. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M: Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999;156:1328–1335.
  4. Hafner H, an der Heiden W: The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999;249(suppl 4):14–26.

    External Resources

  5. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921–928.
  6. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP: Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004;185:291–297.
  7. Beck AT, Rector NA, Stolar N, Grant PM: Schizophrenia: Cognitive Theory, Research and Therapy. New York, Guilford, 2009.
  8. Cane DB, Olinger LJ, Gotlib IH, Kuiper NA: Factor structure of the dysfunctional attitude scale in a student population. J Clin Psychol 1986;42:307–309.

    External Resources

  9. Grant PM, Beck AT: Defeatist beliefs mediate cognitive impairment and negative symptoms in schizophrenia. Schizophr Bull, in press.
  10. Rector NA, Beck AT, Stolar N: The negative symptoms of schizophrenia: a cognitive perspective. Can J Psychiatry 2005;50:247–257.
  11. French P, Morrison AP: Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: a Treatment Approach. London, Wiley, 2004.
  12. Rector NA: Dysfunctional attitudes and symptom expression in schizophrenia: differential associations with paranoid delusions and negative symptoms. J Cogn Psychother 2004;18:163–173.

    External Resources

  13. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A: Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996;22:283–303.
  14. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
  15. Goldberg DP, Hillier VF: A scaled version of the general health questionnaire. Psychol Med 1979;9:139–145.
  16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, American Psychiatric Association, 2000.
  17. Morrison AP, French P, Lewis SW, Roberts M, Raja S, Neil ST, Parker S, Green J, Kilcommons A, Walford L, Bentall RP: Psychological factors in people at ultra-high risk of psychosis: comparisons with non-patients and associations with symptoms. Psychol Med 2006;36:1395–1404.
  18. Weissman AN: Assessing Depressogenic Attitudes: a Validation Study: 51st Annual Meeting of the Eastern Psychological Association, Hartford/CT, 1980.
  19. Andrews JA, Lewinsohn PM, Hops H, Roberts RE: Psychometric properties of scales for the measurement of psychosocial variables associated with depression in adolescence. Psychol Rep 1993;73:1019–1046.
  20. Lewinsohn PM, Allen NB, Seeley JR, Gotlib IH: First onset versus recurrence of depression: differential processes of psychosocial risk. J Abnorm Psychol 1999;108:483–489.
  21. Kaufman NK, Rohde P, Seeley JR, Clarke GN, Stice E: Potential mediators of cognitive-behavioral therapy for adolescents with comorbid major depression and conduct disorder. J Consult Clin Psychol 2005;73:38–46.
  22. Lewinsohn PM, Joiner TE Jr, Rohde P: Evaluation of cognitive diathesis-stress models in predicting major depressive disorder in adolescents. J Abnorm Psychol 2001;110:203–215.
  23. Emsley R, Rabinowitz J, Torreman M: The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res 2003;61:47–57.
  24. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale/NJ, Erlbaum, 1988.
  25. Walker EF, Grimes KE, Davis DM, Smith AJ: Childhood precursors of schizophrenia: facial expressions of emotion. Am J Psychiatry 1993;150:1654–1660.
  26. Beck AT, Steer RA, Brown GK: Manual for the Beck Depression Inventory II. San Antonio/TX, Psychological Corporation, 1996.
  27. Carpenter WT Jr, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578–583.
  28. Buchanan RW: Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007;33:1013–1022.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50